IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
Massimino M, Consoli ML, Mesuraca M, Stagno F, Tirrò E, Stella S, Pennisi MS, Romano C, Buffa P, Bond HM, Morrone G, Sciacca L, Di Raimondo F, Manzella L, Vigneri P.
Massimino M, et al. Among authors: stella s.
Carcinogenesis. 2014 May;35(5):1132-43. doi: 10.1093/carcin/bgu013. Epub 2014 Jan 20.
Carcinogenesis. 2014.
PMID: 24445143